# Semaglutide (EVOKE programme)

Source: https://onco.cc/drugs/da-semaglutide-evoke/  
OnCo record `da-semaglutide-evoke` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Semaglutide is FDA-approved for other indications. Alzheimer’s disease use remains investigational in Phase 3 EVOKE studies, not a dementia label.

## Summary

Existing diabetes or obesity approvals do not equal a dementia indication. Alzheimer’s dosing and benefit are unproven outside trials. Not for self-directed dementia treatment.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Brand: Ozempic / Rybelsus / Wegovy (other indications)
- Modality: small molecule
- Mechanism: GLP-1 receptor agonist; Alzheimer’s cognition outcomes under study in EVOKE trials. Already labelled for diabetes/weight — not for dementia.

## Sources

- ClinicalTrials.gov NCT04777396 (EVOKE): https://clinicaltrials.gov/study/NCT04777396

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mild cognitive impairment](https://onco.cc/diagnoses/mild-cognitive-impairment/)
- companies: [Novo Nordisk](https://onco.cc/companies/da-novo/)
- trials: [EVOKE (semaglutide in early Alzheimer’s)](https://onco.cc/trials/da-trial-evoke/)

---
JSON: https://onco.cc/api/v1/entities/da-semaglutide-evoke.json